Doctors shouldn't get rich from unproven Alzheimer's drug

The Grand Island Independent

Jun 21, 2021

The U.S. Food and Drug Administration's approval last week of Biogen Inc.'s Alzheimer's treatment aducanumab was a mistake based on weak evidence. The question now is just how much…